# EDGAR Filing Document

**Accession Number:** 0001733861
**File Stem:** 0001185185-23-000132
**Filing Date:** 2023-2
**Character Count:** 57001
**Document Hash:** b99a8151fd8410efc7326f373e67e90a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001185185-23-000132.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001185185-23-000132

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 41

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REST EZ Inc.
- **CENTRAL INDEX KEY:** 0001733861
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 824268982
- **STATE OF INCORPORATION:** WY
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56447
- **FILM NUMBER:** 23628245

**BUSINESS ADDRESS:**
- **STREET 1:** 263 EAST 8680 SOUTH
- **CITY:** SANDY
- **STATE:** UT
- **ZIP:** 84070
- **BUSINESS PHONE:** 888-202-9256

**MAIL ADDRESS:**
- **STREET 1:** 263 EAST 8680 SOUTH
- **CITY:** SANDY
- **STATE:** UT
- **ZIP:** 84070

?xml version="1.0" encoding="ASCII"? restez20221231_10q.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 10-Q**

------

(Mark One)

☒ Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarter Ended **December 31, 2022**

☐ Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to .

*Commission file number*: **<u>333-256498</u>**

**<u>REST EZ, INC.</u>**

(Name of Registrant in Its Charter)

---

| | |
|:---|:---|
| **<u>Wyoming</u>** | **<u>82-4268982</u>** |
| (State or Other Jurisdiction of Incorporation or | (I.R.S. Employer Identification No.) |
| Organization) |  |

---

**1398 W. Mason Hollow Dr. <u>Riverton, UT 84065</u>**

(Address of Principal Executive Offices)

**<u>(801) 300-2542</u>**

(Issuer's Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☒ Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of February 8, 2023, there were 20,000,000 shares of the registrant's common stock outstanding.

------

**FORM 10-Q**

**<u>**TABLE OF CONTENTS**</u>**

---

| | | |
|:---|:---|:---|
| [Note About Forward-Looking Statements](#note) | [Note About Forward-Looking Statements](#note) |  |
| **PART I** | **FINANCIAL INFORMATION** |  |
| Item 1. | [Financial Statements](#a1) | 4 |
|  | [Balance Sheets as of December 31, 2022 (Unaudited) and March 31, 2022](#bs) | 4 |
|  | [Statements of Operations for the three and nine months ended December, 2022 and 2021 (Unaudited)](#ops) | 5 |
|  | [Statements of Changes in Stockholders' Equity (Deficit) for the three and nine months ended December 31, 2022 and 2021 (Unaudited)](#se) | 6 |
|  | [Statements of Cash Flows for the nine months ended December 31, 2022 and 2021 (Unaudited)](#cf) | 7 |
|  | [Notes to Financial Statements (Unaudited)](#notes) | 8 |
| Item 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#a2) | 12 |
| Item 4. | [Controls and Procedures](#a4) | 16 |
| **PART II** | **OTHER INFORMATION** |  |
| Item 1. | [Legal Proceedings](#a21) | 17 |
| Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#a22) | 17 |
| Item 3. | [Defaults Upon Senior Securities](#a23) | 17 |
| Item 4. | [Mine Safety Disclosures](#a24) | 17 |
| Item 5. | [Other Information](#a25) | 17 |
| Item 6. | [Exhibits](#a26) | 17 |
|  | [Signatures](#sigs) | 18 |

---

------

**NOTE ABOUT FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, among other things, statements regarding plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements, which are other than statements of historical facts. Forward-looking statements may appear throughout this report, including without limitation, Item 2 "Management's Discussion and Analysis of Financial Condition and Results of Operations." Forward-looking statements generally can be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this report and in our Form S-1/A, and in particular, the risks discussed under the caption "Risk Factors" in Item 1A of this report and in in our Form S-1/A, and those discussed in other documents we file with the Securities and Exchange Commission ("SEC"). Important factors that in our view could cause material adverse effects on our financial condition and results of operations include, but are not limited to, risks associated with service demands and acceptance, our ability to expand, changes in healthcare practices, changes in technology, economic conditions, the impact of competition and pricing, government regulation and approvals, impacts and disruptions caused by the COVID-19 pandemic and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. We undertake no obligation to revise or publicly release the results of any revision to any forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

As used herein, the "Company," "we," "our," and similar terms include Rest EZ, Inc. and its predecessors, unless the context indicates otherwise.

------

[**Table of Contents**](#toc)

**PART I FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**REST EZ, INC.**

**BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **December 31,**  | **March 31,**  |
|  | **2022** | **2022** |
| ASSETS | (unaudited) |  |
| Current assets |  |  |
| Cash | $177 | $431 |
| Deposits | 405000 | 405000 |
| Inventory | 2550 | 2550 |
| Total current assets | 407727 | 407981 |
| Total assets | 407727 | 407981 |
| LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |
| Current liabilities |  |  |
| Accounts payable | 96 |  |
| Income taxes payable | 41687 | 41687 |
| Loan from related party | 129279 | 118450 |
| Total current liabilities | 171062 | 160137 |
| Stockholders' equity |  |  |
| Common stock, $0.001 par value, 100,000,000 shares authorized, 20,000,000 shares issued and outstanding as of December 31, 2022 and March 31, 2022 | 20000 | 20000 |
| Additional paid-in capital | 118962 | 111291 |
| Retained earnings | 97703 | 116553 |
| Total stockholders' equity | 236665 | 247844 |
| Total liabilities and stockholders' equity | $407727 | $407981 |

---

The accompanying notes are an integral part of the unaudited financial statements.

------

[**Table of Contents**](#toc)

**REST EZ, INC.**

**STATEMENTS OF OPERATIONS**

**(UNAUDITED)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the**<br> **Three Months Ended** | **For the**<br> **Three Months Ended** | **For the**<br> **Nine Months Ended** | **For the**<br> **Nine Months Ended** |
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Revenue | $- | $345000 | $- | $519443 |
| Cost of goods sold |  | 165000 |  | 269050 |
| Gross profit |  | 180000 |  | 250393 |
| Operating expenses: |  |  |  |  |
| General and administrative | 2061 | 9875 | 11179 | 23785 |
| Total operating expenses | 2061 | 9875 | 11179 | 23785 |
| Net Operating Income (loss) | (2061) | 170125 | (11179) | 226608 |
| Other income (expense): |  |  |  |  |
| Interest expense | (2586) | (2303) | (7671) | (7615) |
| Total other expense | (2586) | (2303) | (7671) | (7615) |
| Income (loss) before provision for income taxes | (4647) | 167822 | (18850) | 218993 |
| Provision for income taxes |  |  |  |  |
| Net income (loss) | $(4647) | $167822 | $(18850) | $218993 |
| Net income (loss) per share - basic | $(0.00) | $0.01 | $(0.00) | $0.01 |
| Net income (loss) per share - diluted | $(0.00) | $0.01 | $(0.00) | $0.01 |
| Weighted average shares outstanding - basic | 20000000 | 20000000 | 20000000 | 20000000 |
| Weighted average shares outstanding - diluted | 20000000 | 20000000 | 20000000 | 20000000 |

---

The accompanying notes are an integral part of the unaudited financial statements.

------

[**Table of Contents**](#toc)

**REST EZ, INC.**

**STATEMENTS OF CHANGES IN STOCKHOLDERS**' **EQUITY**

**(UNAUDITED)**

**For the Three Months Ended December 31, 2022 and 2021**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  | **Total**  |
|  | **Common Stock**  | **Common Stock**  | **Additional**  |  | **Stockholder's**  |
|  |  |  | **Paid-In**  | **Accumulated**  | **Equity**  |
|  | **Shares**  | **Amount**  | **Capital**  | **Deficit**  | **(Deficit)**  |
| Balance, September 30, 2021 | 20000000 | $20000 | $89019 | $(4247) | $104772 |
| Imputed interest on related party loan |  |  | 2303 |  | 2303 |
| Proceeds from contributed capital |  |  | 17600 |  | 17600 |
| Net income (loss) for the three months ended December 31, 2021 |  |  |  | 167822 | 167822 |
| Balance, December 31, 2021 | 20000000 | $20000 | $108922 | $163575 | $292497 |
| Balance, September 30, 2022 | 20000000 | 20000 | $116376 | $102350 | $238726 |
| Imputed interest on related party loan |  |  | 2586 |  | 2586 |
| Net income (loss) for the three months ended December 31, 2022 |  |  |  | (4647) | (4647) |
| Balance, December 31, 2022 | 20000000 | $20000 | $118962 | $97703 | $236665 |

---

**For the Nine Months Ended December 31, 2022 and 2021**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  | **Total**  |
|  | **Common Stock** | **Common Stock** | **Additional** |  | **Stockholder's**  |
|  |  |  | **Paid-In**  | **Accumulated**  | **Equity**  |
|  | **Shares**  | **Amount**  | **Capital**  | **Deficit**  | **(Deficit)**  |
| Balance, March 31, 2021 | 20000000 | $20000 | $21307 | $(55418) | $(14111) |
| Imputed interest on related party loan |  |  | 7615 |  | 7615 |
| Proceeds from contributed capital |  |  | 80000 |  | 80000 |
| Net income (loss) for the nine months ended December, 2021 |  |  |  | 218993 | 218993 |
| Balance, December 31, 2021 | 20000000 | $20000 | $108922 | $163575 | $292497 |
| Balance, March 31, 2022 | 20000000 | $20000 | $111291 | $116553 | $247844 |
| Imputed interest on related party loan |  |  | 7671 |  | 7671 |
| Net income (loss) for the nine months ended December 31, 2022 |  |  |  | (18850) | (18850) |
| Balance, December 31, 2022 | 20000000 | $20000 | $118962 | $97703 | $236665 |

---

The accompanying notes are an integral part of the unaudited financial statements.

------

[**Table of Contents**](#toc)

**REST EZ, INC.**

**STATEMENTS OF CASH FLOWS**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **For the** | **For the** |
|  | **Nine Months Ended** | **Nine Months Ended** |
|  | **December 31,** | **December 31,** |
|  | **2022** | **2021** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| Net income (loss) | $(18850) | $218993 |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Imputed interest on related party loan | 7671 | 7615 |
| Changes in assets and liabilities: |  |  |
| Deposits |  | (324850) |
| Inventory |  | 23900 |
| Accounts payable | 96 |  |
| Net cash provided by (used in) operating activities | (11083) | (74342) |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |
| Proceeds from contributed capital |  | 80000 |
| Proceeds from (repayments of) related party debt | 10829 | (17925) |
| Net cash provided by financing activities | 10829 | 62075 |
| Net decrease in cash and cash equivalents | (254) | (12267) |
| Cash and cash equivalents at beginning of period | 431 | 12350 |
| Cash and cash equivalents at end of period | $177 | $83 |
| **SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:** |  |  |
| Interest paid | $- | $- |
| Income taxes paid | $- | $- |
| **NON-CASH INVESTING AND FINANCING ACTIVITIES:** |  |  |
| None. |  |  |

---

The accompanying notes are an integral part of the unaudited financial statements.

------

[**Table of Contents**](#toc)

**REST EZ, INC.**

**NOTES TO UNAUDITED FINANCIAL STATEMENTS**

**December 31, 2022**

**Note 1. General Organization and Business**

Rest EZ, Inc. (the "Company") was incorporated on October 17, 2016. The Company has passed through all stages of development to full operations from incorporation, at the present time the company is currently in full Production and Distribution to wholesalers and retailers as well as online at www.RestEz.net. Rest EZ Inc. has commenced its major operations of having one product a liquid gel capsule named Rest EZ Sleep Aid Supplement, manufactured by an unaffiliated outside provider (Sport Energy) that manufactures liquid gels to various Companies, but has not distributed this product to anyone except Rest EZ Inc.

The Company's year-end is March 31.

**Note 2. Summary of Significant Accounting Policies**

**Basis of Presentation**

The financial statements have been prepared in accordance with United States generally accepted accounting principles and reflect all adjustments which, in the opinion of management, are necessary for a fair presentation. All such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company's financial statements for the year ended March 31, 2022 contained in the Company's annual report on 10-K filed with the SEC on July 14, 2022.

**Use of Estimates**

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and disclosure of contingent liabilities in advance of all conditions being met at the date of the financial statements. Actual results could differ from those estimates.

**Fair Value of Financial Instruments**

The Company's balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization.

FASB Accounting Standards Codification (ASC) 820 *Fair Value Measurements and Disclosures* (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

---

| | |
|:---|:---|
| Level 1 - | Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. |
| Level 2 - | Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. |
| Level 3 - | Inputs that are both significant to the fair value measurement and unobservable. |

---

The adoption of this standard did not have a material effect on the Company's financial statements as reflected herein. The carrying amounts of cash and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company had no items that required fair value measurement on a recurring basis.

------

[**Table of Contents**](#toc)

**Revenue Recognition**

The Company recognizes revenue from product sales upon product delivery. All of our products are shipped through a third-party fulfillment center to the customer and the customer takes title to product and assumes risk and ownership of the product when it is delivered. Shipping charges to customers and sales taxes collectible from customers, if any, are included in revenues. Deferred revenue recorded on the balance sheet represents payments received by the Company in advance of the product being delivered.

We adopted ASC Topic 606, "Revenue from Contracts with Customers", and all related interpretations for recognition of our revenue. Under ASC 606, the Company recognizes revenue from the commercial sales of products by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied.

There was no revenue during the nine months ended December 31, 2022; all revenue during the nine months ended December 31, 2021 was from product sales.

**Cash and Cash Equivalents**

All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $177 and $431 as of December 31, 2022 and March 31, 2022, respectively. There were no cash equivalents as of December 31, 2022 and March 31, 2022. The Federal Deposit Insurance Corporation ("FDIC") insures these balances up to $250,000. At December 31, 2022 and March 31, 2022, cash in excess of the insured amount was $0.

**Inventories**

Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company's determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management's future plans.

**Income Taxes**

The Company accounts for income taxes under ASC 740 *Income Taxes*. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of December 31, 2022 and March 31, 2022.

**Commitments and Contingencies**

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of December 31, 2022 and March 31, 2022.

**Recently Issued Accounting Pronouncements**

From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company's financial position or results of operations upon adoption.

There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.

------

[**Table of Contents**](#toc)

**Note 3. Going Concern**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended December 31, 2022, the Company had a net loss of $18,850. As of December 31, 2022, the Company had net working capital of $236,665 and retained earnings of $97,703. The Company has begun to recognize revenue, but without additional capital, the Company may not be able to remain in business. The continuation of the Company as a going concern is dependent upon (i) its ability to identify future investment opportunities, (ii) its ability to obtain any necessary debt and/or equity financing, which may include loans from related parties, and (iii) its ability to generate profits from the Company's future operations.

These factors raise a substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

Achievement of the Rest EZ, Inc.'s business objective is basically dependent upon the judgment, skill and knowledge of the Company's management. Mr. Sosa is currently the Company's sole executive officer and director. There can be no assurance that a suitable replacement could be found for our sole executive officer and director upon his retirement, resignation, inability to act on our behalf, or death.

**Note 4. Deposits**

The Company deposits funds with its supplier in advance of inventory purchases. The amount of outstanding deposits at December 31, 2022 and March 31, 2022 was $405,000.

**Note 5. Inventory**

Inventory consists of one product, a liquid gel capsule named Rest EZ Sleep Aid Supplement, manufactured by an unaffiliated outside provider. At December 31, 2022 and March 31, 2022, inventory consisted of the following:

---

| | | |
|:---|:---|:---|
|  | **December 31, 2022** | **March 31, 2022** |
| Finished Goods Inventory | $2550 | $2550 |

---

**Note 6. Related Party Transactions**

As of December 31, 2022 and March 31, 2022, Brandon Sosa, President and sole stockholder of the Company, had loaned the Company the amount of $129,279 and $118,450, respectively, for operating capital. During the nine months ended December 31, 2022 and 2021, the Company charged to operations the amount of $7,671 and $7,615, respectively, as imputed interest on these loans.

During the nine months ended December 31, 2021, the Company's founder and CEO sold 8,000,000 shares of common stock he personally owned to outside investors and contributed the proceeds in the amount of $80,000 to the Company. This amount is recorded as proceeds from contributed capital on the Company's statement of changes in stockholder's equity. See note 7.

**Note 7. Stockholders**' **Equity**

The Company has 100,000,000 authorized shares of common stock with $0.001 par value. As of December 31, 2022 and March 31, 2022, there were 20,000,000 shares of common stock outstanding.

During the nine months ended December 31, 2021, Brandon Sosa, the Company's founder and CEO, sold 8,000,000 shares of common stock he personally owned to outside investors at a price of $0.01 per share. See note 6. Proceeds in the net amount of $80,000 were contributed to the Company, and are recorded as contributed capital on the Company's statement of stockholder's equity (deficit) at December 31, 2021. Previous to this sale of shares, Mr. Sosa owned 20,000,000 shares of the Company's common stock; subsequent to this sale of shares, Mr. Sosa owned 12,000,000 shares of the Company's common stock.

On October 17, 2016, the Company issued 20,000,000 shares of common stock to Brandon Sosa, the Company's President, in exchange for $20,000.

On May 26, 2021, the Company filed a Form S-1 with the Securities Exchange Commission in order to register the Company's currently outstanding 20,000,000 shares of common stock. This registration statement became effective on July 19, 2021.

------

[**Table of Contents**](#toc)

**Note 8. Income Taxes**

There is no current or deferred income tax expense or benefit for the period ended December 31, 2022.

The Company has not recognized an income tax expense or benefit for the period based on uncertainties concerning its ability to generate taxable income in future periods. The tax expense for the current period presented is offset by a valuation allowance (100%) established against deferred tax assets arising from operating losses and other temporary differences, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not.

At December 31, 2022 and March 31, 2022, the Company had a net operating loss carryforward in the amount of $0.

**Note 9. Subsequent Events**

The Company has evaluated events occurring subsequent to December 31, 2022 through the date these financial statements were issued and noted no items requiring disclosure.

------

[**Table of Contents**](#toc)

**ITEM 2. MANAGEMENT**'**S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Forward Looking Statements**

The following discussion should be read in conjunction with the consolidated financial statements and the related notes thereto, as well as all other related notes, and financial and operational references, appearing elsewhere in this document.

● Our ability to raise capital necessary to sustain our anticipated operations and implement our business plan,

● Our ability to implement our business plan,

● Our ability to generate sufficient cash to pay our lenders and other creditors,

● Our ability to employ and retain qualified management and employees,

● Our dependence on the efforts and abilities of our current employees and executive officers,

● Changes in government regulations that are applicable to our current or anticipated business,

● Changes in the demand for our services and different food trends,

● The degree and nature of our competition,

● The lack of diversification of our business plan,

● The general volatility of the capital markets and the establishment of a market for our shares, and

● Disruption in the economic and financial conditions primarily from the impact of past terrorist attacks in the United States, threats of future attacks, police and military activities overseas and other disruptive worldwide political and economic events, health pandemics and environmental weather conditions.

We are also subject to other risks detailed from time to time in our other filings with the SEC and elsewhere in this report. Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

------

[**Table of Contents**](#toc)

**Critical Accounting Policy and Estimates**

<u>Use of Estimates in the Preparation of Financial Statements</u>

The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. These estimates include certain assumptions related to doubtful accounts receivable, stock-based services, valuation of financial instruments, operating right of use assets and liabilities, and income taxes. On an on-going basis, we evaluate these estimates, including those related to revenue recognition and concentration of credit risk. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Accounts subject to estimate and judgements are accounts receivable reserves, income taxes, intangible assets, contingent liabilities, and equity based instruments. Actual results may differ from these estimates under different assumptions or conditions. We believe our estimates have not been materially inaccurate in past years, and our assumptions are not likely to change in the foreseeable future.

<u>Fair Value of Financial Instruments</u>

The Company measures its financial assets and liabilities in accordance with accounting principles generally accepted in the United States of America. The estimated fair values approximate their carrying value because of the short-term maturity of these instruments or the stated interest rates are indicative of market interest rates. These fair values have historically varied due to the market price of the Company's stock at the date of valuation.

<u>Income Taxes</u>

The Company uses the liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to financial statements carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. The measurement of deferred tax assets and liabilities is based on provisions of applicable tax law. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance based on the amount of tax benefits that, based on available evidence, is not expected to be realized.

**Background**

We were incorporated in the State of Wyoming on October 17, 2016, under the name of Amazing Ventures, Inc. Our articles of incorporation were amended on February 12, 2018 to change our name to Rest EZ, Inc.

Rest EZ, Inc. is in full production with product distribution to wholesalers and retailers as well as being available online at www.RestEz.net. Rest EZ Inc. has one sleep liquid gel capsule (named Rest EZ Sleep Aid Supplement).

**General Introduction**

Rest EZ, Inc. is currently in full production with full product distribution to wholesalers and retailers as well as online at www.RestEz.net. Rest EZ Inc. has commenced its major operations of having one product, a liquid gel capsule named Rest EZ Sleep Aid Supplement, manufactured by an unaffiliated outside provider (Sport Energy) that manufactures liquid gels to various companies, but has not distributed this product to anyone except Rest EZ, Inc. The Company is presently marketing the Rest EZ Sleep Aid Supplement to wholesalers, retailers, and online at www.RestEz.net. Rest EZ, Inc. is considered a Full Production and Full Distribution stage company because it has commenced all major operations with outside wholesalers and retailers, and has sold 77,694 bottles for $664,943 in total sales, with an retained earnings of $97,703 through December 31, 2022.

The product is a liquid gel capsule containing soybean oil, gelatin, valerian root, rosehips extract, purified water, yellow beeswax, L-Theanine, L-Threonine, lecithin, St. John's Wort extract, lemon balm leaf extract, niacin and melatonin. The product is to be taken orally, preferably with water, at bedtime. Upon digestion the product is absorbed within the bloodstream ultimately providing the user an enhanced ability to sleep. One serving is two capsules per day. Intended customers are adults (persons over 18 years of age) who experience difficulty with sleeping.

------

[**Table of Contents**](#toc)

Beyond the general FDA requirement that every dietary supplement be labeled as such, either with the term "dietary supplement" or with a term that substitutes a description of the product's dietary ingredient(s) for the word "dietary" (e.g., "herbal supplement" or "calcium supplement"), and the FDA's safety monitoring responsibilities for dietary supplement firms once a dietary supplement is on the market, there are no additional FDA requirements specific to this product, and federal law does not require dietary supplements to be proven safe to FDA's satisfaction before they are marketed. Rest EZ, Inc. has not sent the product to the FDA for approval because it is not required, and because it would be a lengthy and costly process to have this product FDA approved when not required.

The liquid gel capsules are manufactured by Sport Energy, who adheres to very strict guidelines placed upon them by all agencies with whom they work. Sport Energy indicated they may use other outside sources to produce our product but has verbally indicated that all their ingredients used in any consumable products are very closely monitored. The manufacturer is registered as a Good Manufacturing Practices (GMP) company with NSF's Dietary Supplement Certification program and the Natural Products Association (NPA), a status they have held for many years. Manufacturing of the capsules is complete, although manufacturing of the capsules will be ongoing as supply and demand dictates.

Rest EZ, Inc. has nothing proprietary about their product. At this time, Rest EZ, Inc. has no intellectual properties in connection with the capsules. However, we believe our product is superior to that of the competition due to the product being in a soft gel form, avoiding substantial product break down before digestion as happens with many competitors' products.

The competition for and difficulty in selling a sleeping aid supplement product may affect our ability to maintain profitable operations in the future. Companies that are engaged in this product market include large, established companies with substantial capabilities and long earnings records.

The Company has minimal revenue. Without additional capital, the Company will not be able to remain in business. These factors raise a substantial doubt about the Company's ability to continue as a going concern. Company financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. Achievement of the Rest EZ, Inc.'s business objective is basically dependent upon the judgment, skill and knowledge the Company's management. Mr. Sosa is currently the Company's sole executive officer and director. There can be no assurance that a suitable replacement could be found for our sole executive officer and director upon his retirement, resignation, inability to act on our behalf, or death. Should the Company be unable to raise additional financing it would be unable to remain in business.

**Business Development** 

The Company was incorporated on October 17, 2016. The Company has passed through all stages of development to full operations from incorporation, and the Company is currently in full production and distribution to wholesalers and retailers as well as online at www.RestEz.net.

<u>Initial Sales Strategy</u>

We have established a very strong sales approach; our approach utilizes direct sales through Mr. Sosa to our wholesalers and retailers as well as our company's professional and easy to use web site. Our direct sales will be conducted by Mr. Sosa. He will market the product to wholesalers nationally, to retail chain stores and worldwide distributors. The Company's current marketing strategy consists of various Point of Sale materials to include advertising posters, flyers and magnetic strips with the Company's name and its product developed by Mr. Sosa in the past several months. In addition, sales will be done with referrals, distribution by our wholesalers and online marketing at www.RestEz.net

**Description of Property**

The Company uses a corporate office located at: 1398 W. Mason Hollow Drive, Riverton, Utah 84065. This facility is being provided to the Company free of charge by Mr. Sosa. Mr. Sosa is providing his own facility free of charge until the company needs additional space to store inventory over 100,000 bottles. Mr. Sosa indicates he has enough room to store 100,000 bottles of Rest EZ product, so no additional room is needed at this time, or in the near future. There are currently no proposed programs for renovations, improvements or developments of the facility currently in use.

------

[**Table of Contents**](#toc)

**Results of Operations**

For the three months ended December 31, 2022 and 2021, the Company had a gross profit of $0 and $180,000, respectively. Selling, general and administrative expenses were $2,061 and $9,875 for the three months ended December 31, 2022 and 2021, respectively. Interest expense, which consisted of imputed interest on related party loans, was $2,586 and $2,303 for the three months ended December 31, 2022 and 2021, respectively. This resulted in the company generating a net loss of $4,647 during the three months ended December 31, 2022, compared to net income of $167,822 during the three months ended December 31, 2021.

For the nine months ended December 31, 2022 and 2021, the Company had a gross profit of $0 and $250,393, respectively. Selling, general and administrative expenses were $11,179 and $23,785 for the nine months ended December 31, 2022 and 2021, respectively. Interest expense, which consisted of imputed interest on related party loans, was $7,671 and $7,615 for the nine months ended December 31, 2022 and 2021, respectively. This resulted in the company generating a net loss of $18,850 during the nine months ended December 31, 2022, compared to net income of $218,993 during the nine months ended December 31, 2021.

**Liquidity and Capital Resources**

For the nine months ended December 31, 2022, cash used in operating activities was $11,083, consisting of our net loss of $18,850, interest on related party debt of $7,671 and an increase in accounts payable of $96; compared to $74,342, consisting of net income of $218,993, imputed interest on related party debt of $7,615, a decrease in deposits of $324,850, and an increase in inventory of $23,900, for the nine months ended December 31, 2021. For the nine months ended December 31, 2022, cash provided by financing activities was $10,829, consisting of proceeds from related party debt for operating expenses. Cash provided by financing activities for the nine months ended December 31, 2021 was $62,075, consisting of proceeds from contributed capital of $80,000 offset by repayments of related party debt of $17,925.

**Plan of Operation**

We have established a very strong sales approach; our approach utilizes direct sales through Mr. Sosa to our wholesalers and retailers as well as our company's professional and easy to use web site. Our direct sales will be conducted by Mr. Sosa. He will market the product to wholesalers nationally, to retail chain stores and worldwide distributors. The Company's current marketing strategy consists of various Point of Sale materials to include advertising posters, flyers and magnetic strips with the Company's name and its product developed by Mr. Sosa in the past several months. In addition, sales will be done with referrals, distribution by our wholesalers and online marketing at www.restez.net

Over the next twelve months, Rest EZ, Inc. plans to build out its reputation further, and expand to additional wholesalers, retail chain stores, as well as expand sales to the public.

**Off-Balance Sheet Arrangements**

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues, or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

**Inflation**

In the opinion of management, inflation has not had a material effect on the Company's financial condition or results of its operations.

**Going Concern Considerations**

The accompanying financial states have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company suffered a net loss from operations and has a net capital deficiency, which raises substantial doubt about its ability to continue as a going concern. Management's plans regarding those matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**Risk Factors** 

The Company's business and success is subject to numerous risk factors as detailed in its Form S-1/A and other of its Current Reports on Form 8-K all of which reports are available at no cost at <u>www.sec.gov</u>.

------

[**Table of Contents**](#toc)

**ITEM 4. CONTROLS AND PROCEDURES**

As of December 31, 2022 (the "Evaluation Date"), the Company's management evaluated, with participation of its principal executive officer, the effectiveness of the Company's disclosure controls and procedures, as defined in Rules 13a-15 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based on that evaluation, the Company's principal executive officer concluded that the Company's disclosure controls and procedures were ineffective as of December 31, 2022.

Management assessed the effectiveness of its internal control over financial reporting as of the Evaluation Date based on criteria for effective internal control over financial reporting described in Internal Control—Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. The material weaknesses identified during management's assessment were (i) a lack of sufficient internal accounting resources; (ii) a lack of segregation of duties to ensure adequate review of financial statement preparation, (iii) lack of an independent board of directors or audit committee, and (iv) lack of written documentation of our internal control policies and procedures. In light of these material weaknesses, management has concluded that we did not maintain effective internal control over financial reporting at the Evaluation Date.

------

[**Table of Contents**](#toc)

**PART II OTHER INFORMATION**

**ITEM 1. Legal Proceedings**

None.

**ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds**

None.

**ITEM 3. Defaults Upon Senior Securities**

None.

**ITEM 4. Mine Safety Disclosures**

Not applicable.

**ITEM 5. Other Information**

None.

**ITEM 6. Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 3.1\* | [Articles of Incorporation](http://www.sec.gov/Archives/edgar/data/1733861/000118518521000731/ex_251196.htm) |
| 3.2\* | [Amended Articles of Incorporation for Name Change to Rest EZ](http://www.sec.gov/Archives/edgar/data/1733861/000118518521000731/ex_251197.htm) |
| 3.3\* | [Amended Articles of Incorporation for Name Change to Rest EZ, Inc.](http://www.sec.gov/Archives/edgar/data/1733861/000118518521000731/ex_251198.htm) |
| 3.4\* | [Bylaws](http://www.sec.gov/Archives/edgar/data/1733861/000118518521000731/ex_251199.htm) |
| 31.1 | [Section 302 Certification](ex_473325.htm) |
| 31.2 | [Section 302 Certification](ex_473326.htm) |
| 32.1 | [Section 906 Certification](ex_473327.htm) |
| 32.2 | [Section 906 Certification](ex_473328.htm) |
| 101.INS | Inline XBRL Instance Document |
| 101.SCH | Inline XBRL Taxonomy Extension Schema |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase |
| 101.DEF | Inline XBRL Taxonomy Extension Definitions Linkbase |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

---

\* Previously filed with the Company's Form S-1 filed with the Securities and Exchange Commission on May 26, 2021.

------

[**Table of Contents**](#toc)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
|  | **Rest EZ, Inc.** |
| Date: February 14, 2023 | By: /s/ Brandon Sosa |
|  | Brandon Sosa |
|  | President, Chief Executive Officer (Principal Executive Officer) |

---

---

| | |
|:---|:---|
| Date: February 14, 2023 | By: /s/ Brandon Sosa |
|  | Brandon Sosa |
|  | Chief Financial Officer (Principal Financial and Accounting Officer) |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION PURSUANT TO SECTION 302 OF THE**

**SARBANES-OXLEY ACT OF 2002**

I, Brandon Sosa, Chief Executive Officer of Rest EZ, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Rest EZ, Inc. for the quarter ended December 31, 2022;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d- 15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the issuer's internal control over financial reporting that occurred during the issuer's most recent fiscal year that has materially affected, or is reasonably likely to materially affect, the issuer's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the issuer's independent registered public accounting firm and the audit committee of the issuer's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: February 14, 2023 | By: /s/ Brandon Sosa |
|  | Brandon Sosa |
|  | Chief Executive Officer (Principal Executive Officer) |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**CERTIFICATION PURSUANT TO SECTION 302 OF THE**

**SARBANES-OXLEY ACT OF 2002**

I, Brandon Sosa, the Chief Financial Officer of Rest EZ, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Rest EZ, Inc. for the quarter ended December 31, 2022;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d- 15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the issuer's internal control over financial reporting that occurred during the issuer's most recent fiscal year that has materially affected, or is reasonably likely to materially affect, the issuer's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the issuer's independent registered public accounting firm and the audit committee of the issuer's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: February 14, 2023 | By: /s/ Brandon Sosa |
|  | Brandon Sosa |
|  | Chief Financial Officer (Principal Financial Officer) |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO RULE 13a-14(b) OR**

**RULE 15d-14(b) and 18 U.S.C.** §**1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of Rest EZ, Inc. (the "Company") on Form 10-Q for the quarter ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Brandon Sosa, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: February 14, 2023 | By: /s/ Brandon Sosa |
|  | Brandon Sosa |
|  | President, Chief Executive Officer (Principal Executive Officer) |

---

## Exhibit 32.2

**EXHIBIT 32.2**

**CERTIFICATION PURSUANT TO RULE 13a-14(b) OR**

**RULE 15d-14(b) and 18 U.S.C.** §**1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of Rest EZ, Inc. (the "Company") on Form 10-Q for the quarter ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Brandon Sosa, the Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: February 14, 2023 | By: /s/ Brandon Sosa |
|  | Brandon Sosa |
|  | Chief Financial Officer (Principal Financial and Accounting Officer) |

---